Enhancement of DNA vaccine potency using conventional aluminum adjuvants

Ulmer, Jeffrey B.; DeWitt, Corrille M.; Chastain, Michael; Friedman, Arthur; Donnelly, John; McClements, William L.; Caulfield, Michael J.; Bohannon, Kathryn E.; Volkin, David B.; Evans, Robert K.

doi:10.1016/s0264-410x(99)00151-6

Cited by 128 publications

(67 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[23][24][25] Many strategies have been used in an attempt to enhance the immunogenicity of DNA vaccines. [26][27][28][29][30][31] It is evident that the potencies of these vaccines depends on amount of the antigen expressed in transfected cells. 6 Therefore, a successful DNA vaccine strategy requires both the efficient delivery of DNA into somatic cells and the appropriate expression of the gene products in the targeted cells.…”

Section: Discussionmentioning

confidence: 99%

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity

Choi¹,

Jeon²,

Kang³

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Human sodium iodide symporter (hNIS) is a transmembrane protein that actively transports iodide ions into thyroid cells. hNIS is over-expressed in some cases of the thyroid cancers compared with the surrounding normal tissues and has been considered to be an attractive target for immunotherapy. The aim of this study is to determine the feasibility of utilizing the hNIS antigenic protein in enhanced-antigen-associated immunotherapy using image analysis with a gamma counter. To accomplish this, minimalistic immunogenically defined gene expression (MIDGE), either plain or coupled to a nuclear localization signal (NLS) peptide, was used as a vector system. Vaccination with MIDGE/hNIS, MIDGE/ hNIS-NLS and pcDNA3.1/hNIS produced a significant increase in the number of hNIS-associated IFN-c-secreting CD8 1 T cells, with MIDGE/hNIS having the strongest effect. In addition, immunization with the hNIS encoding vectors induced antigen-mediated antitumor activity against NIS-expressing CT26 tumors in vivo, with the highest tumor free rate (100%) and lowest tumor growth being observed up to 40 days after the CT26/NIS tumor challenge with MIDGE/hNIS than those resulting from other immunization groups. Tumor progression could be followed noninvasively and repetitively by monitoring levels of hNIS gene expression in the tumors using scintigraphic image analysis. Overall, hNIS has a potential use as an antigen for immunization approaches, and vaccination with MIDGE/hNIS vectors is an effective means of generating hNIS-associated immune responses in mice. ' 2007 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity

Choi¹,

Jeon²,

Kang³

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Microparticulates include DNA adsorbed to or entrapped in biodegradable microparticles such as poly-lactide-co-glycolide or chitosan, or complexed with nonionic block copolymers or polycations such as polyethyleneimine (39,41,42). Among the classical adjuvants, aluminum phosphate is noteworthy for its effectiveness and simplicity of preparation (43). Microparticulates appear to improve delivery of DNA to APCs by facilitating trafficking to local lymphoid tissue via the afferent lymph and facilitating uptake by dendritic cells (44 -46).…”

Section: Formulations and Targetingmentioning

confidence: 99%

DNA Vaccines: Progress and Challenges

Donnelly

Wahrén²,

Liu³

2005

The Journal of Immunology

403

245

View full text Add to dashboard Cite

In the years following the publication of the initial in vivo demonstration of the ability of plasmid DNA to generate protective immune responses, DNA vaccines have entered into a variety of human clinical trials for vaccines against various infectious diseases and for therapies against cancer, and are in development for therapies against autoimmune diseases and allergy. They also have become a widely used laboratory tool for a variety of applications ranging from proteomics to understanding Ag presentation and cross-priming. Despite their rapid and widespread development and the commonplace usage of the term “DNA vaccines,” however, the disappointing potency of the DNA vaccines in humans underscores the challenges encountered in the efforts to translate efficacy in preclinical models into clinical realities. This review will provide a brief background of DNA vaccines including the insights gained about the varied immunological mechanisms that play a role in their ability to generate immune responses.

show abstract

“…However, the enhancing effect of aluminium hydroxide on the immune response elicited by DNA vaccines, is not related to the levels of antigen expression. Rather, it seems to affect antigen after in vivo expression, suggesting the adjuvanticity of this substance is strictly related to the antigen delivery mechanism (Ulmer et al 1999). …”

Section: Aluminium-based Compoundsmentioning

confidence: 99%

DNA Vaccination by Electrogene Transfer

Chiarella¹,

Fazio²,

Signori³

2011

Non-Viral Gene Therapy

View full text Add to dashboard Cite

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

Cited by 128 publications

References 36 publications

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity

DNA Vaccines: Progress and Challenges

DNA Vaccination by Electrogene Transfer

Contact Info

Product

Resources

About

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

Cited by 128 publications

References 36 publications

MIDGE/hNIS vaccination generates antigen‐associated CD8+IFN‐γ+ T cells and enhances protective antitumor immunity

MIDGE/hNIS vaccination generates antigen‐associated CD8+IFN‐γ+ T cells and enhances protective antitumor immunity

DNA Vaccines: Progress and Challenges

DNA Vaccination by Electrogene Transfer

Contact Info

Product

Resources

About

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity

MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity